| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2889 |
| Trial ID | NCT05191472 |
| Disease | Multiple Myeloma | Plasma Cell Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA CAR-T cells |
| Co-treatment | Pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies |
| Year | 2022 |
| Country | United States |
| Company sponsor | Alfred Chung, MD |
| Other ID(s) | 212530|NCI-2021-13897 |
| Cohort 1 | |||||||
|
|||||||